Financing led by RA Capital Managementwith participation from Perceptive Advisors, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and […]
Read More… from Forge Biologics Announces Closing of $120 Million Series B Financing
COLUMBUS, OHIO April 22, 2021 – Forge Biologics, a hybrid gene therapy contract manufacturing, and clinical stage therapeutic development company, […]
COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller, […]
The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients […]
We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing […]
We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements. […]
We are thrilled to have a spotlight in National Venture Capital Association‘s (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive […]
Read More… from “Building Better” Blog: Forge Biologics Spotlight
With new beginnings comes new hope. As we enter 2021, screening will begin for the our Phase 1/2 RESKUE trial […]
Read More… from RESKUE Trial for Patients with Krabbe Disease
As we begin 2021, we’d like to introduce you to our new Blaze Vector™ AAV production line. Utilizing our proprietary […]